• The Korean Journal of Pain
• /
• v.7 no.1
• /
• pp.1-12
• /
• 1994

• Asian Oncology Nursing
• /
• v.1 no.2
• /
• pp.157-167
• /
• 2001

Purpose : This study was 1) to determine the relationship between endogenous opioid-peptides and hope 2) to evaluate the availability of the opioid- peptides, known as biochemicals of emotion in psychoneuroimmunology, as a variable to explain hope. Method : blood sampling for 20 cancer patients' (age range 18-73, 13 men and 7 women, having mild pain or no pain, can do ADL) were made under approval from the doctors in a university hospital at 8 A.M. and quantitative analysis of opioid peptides were done by the internal standard method. In 10min after blood sampling, hope was measured using Kim and Lee's hope scale which had acceptable reliabilities and validity after making consent about interviewing. Blood was sampled from the seven normal adults for comparing the degrees of the opioids. None-parametric statistical analysis was used. Results : There was a significant difference in leucine enkephalin between normal adults and cancer patients. And significant positive relationship existed between chemotherapy and leucine enkephalin. So, the relationships between hope and the endogenous opioids in the patients before chemotherapy were re-tested, excluding the effect of chemotherapy on opioids. As a result, a significant negative relationship between hope and beta- endorphin(r=-.841<.05) showed. And there were highly negative relationships between leucine enkephalin and methionine enkephalin and hope, but not significant statistically. Conclusions : This results implies endogenous opioids can be used as a biological variable to explain hope. More researches in sophisticated design would be needed ,especially in human model.

• Korean Journal of Biological Psychiatry
• /
• v.5 no.1
• /
• pp.34-45
• /
• 1998

We provide the reader with a brief introduction to the neurobiology of neuropeptides. Several comprehensive reviews of the distribution and neurochemical, neurophysiological, neuropharmacological and behavioral effects of the major neuropeptides have recently appeared. In reviews of the large number of neuropeptides in brain and their occurance in brain regions thought to be involved in the pathogenesis of major psychiatric disorders, investigators have sought to determine whether alternations in neuropeptide systems are associated with schizophrenia, mood disorders, anxiety disorders, alcoholism and neurodegenerative disease. There is no longer any doubt that neuropeptide-containing neurons are altered in several neuropsychiatric disorders. One of the factors that has hindered neuropeptide research to a considerable extent is the lack of pharmacological agents that specifically alter the synaptic availability of neuropeptides. With the exception of naloxone and naltrexone, the opiate-receptor antagonists, there are few available neuropeptide- receptor antagonists. Two independent classes of neuropeptide-receptor antagonists has been expected to be clinically useful. Naltrexone, a potent ${\mu}$-receptor antagonist, has been used successfully to reduce the need for alcohol consumption. And cholecycstokinin antagonists are now in development as a new class of anxiolytics, which would be expected to be free from tolerance and physical dependence and lack of sedation. In this review, we deal with these two kinds of neuropeptide system, the opioid system and cholesystokinins in the brain. The role of opioid systems in the reinforcement after alcohol consumtion and that of cholesystokinins in the pathogenesis of anxiety will be discussed briefly. As we know, the future for neuropeptides in psychiatry remains bright indeed.